

Short Bio

Andrew M. Scharenberg, MD, is an Attending Physician at Seattle Children's Hospital, a Professor in the Department of Pediatrics, and an Adjunct Professor in the Department of Immunology at the University of Washington School of Medicine in Seattle. He presently serves as Chief Scientific Officer of Casebia Therapeutics in Cambridge, MA.

Prior to joining Casebia, Dr. Scharenberg co-directed (with David Rawlings M.D.) the Program in Cell and Gene Therapy at Seattle Children's Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. This work led to the development of a program in engineered regulatory T-cells, recently partnered with Casebia for the purpose of developing gene edited cell therapeutics for IPEX syndrome. Dr Scharenberg also is a past Chief Scientific Officer of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T-cell platform, and past co-founder of Pregenen Inc., a gene editing and cell-signalling technology company that was acquired by bluebird bio in 2014.

He earned his medical degree from the University of North Carolina School of Medicine, and then completed residency training in pediatrics at the University of North Carolina Children's Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital.

Dr Scharenberg received the American Pediatric Society/Society for Pediatric Research National Young Investigator Award in 2002. He is an active member of the American Society for Clinical Investigation and the American Pediatric Society.